Perspectives of Next-Generation Live-Attenuated Rift Valley Fever Vaccines for Animal and Human Use

Paul J. Wichgers Schreur, Brian H. Bird, Tetsuro Ikegami, Erick Bermúdez-Méndez, Jeroen Kortekaas

Research output: Contribution to journalReview articlepeer-review


Live-attenuated Rift Valley fever (RVF) vaccines transiently replicate in the vaccinated host, thereby effectively initiating an innate and adaptive immune response. Rift Valley fever virus (RVFV)-specific neutralizing antibodies are considered the main correlate of protection. Vaccination with classical live-attenuated RVF vaccines during gestation in livestock has been associated with fetal malformations, stillbirths, and fetal demise. Facilitated by an increased understanding of the RVFV infection and replication cycle and availability of reverse genetics systems, novel rationally-designed live-attenuated candidate RVF vaccines with improved safety profiles have been developed. Several of these experimental vaccines are currently advancing beyond the proof-of-concept phase and are being evaluated for application in both animals and humans. We here provide perspectives on some of these next-generation live-attenuated RVF vaccines and highlight the opportunities and challenges of these approaches to improve global health.

Original languageEnglish (US)
Article number707
Issue number3
StatePublished - Mar 2023


  • Rift Valley fever virus
  • live-attenuated
  • next-generation
  • reverse genetics
  • vaccine

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Drug Discovery
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'Perspectives of Next-Generation Live-Attenuated Rift Valley Fever Vaccines for Animal and Human Use'. Together they form a unique fingerprint.

Cite this